LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer
Oncotarget, ISSN: 1949-2553, Vol: 5, Issue: 4, Page: 970-977
2014
- 24Citations
- 16Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations24
- Citation Indexes24
- 24
- CrossRef19
- Captures16
- Readers16
- 16
Article Description
The Leucine Zipper Tumor Suppressor 1 (LZTS1) is a tumor suppressor gene, located at chromosome 8p22, which is frequently altered in human cancer. In normal tissue, its ubiquitous expression regulates cell mitosis by the stabilization of microtubule networks. LZTS1-deficient mouse embryonic fibroblasts have been shown to have an accelerated mitotic progression, and a higher resistance to taxanes, microtubule-stabilizing drugs. We investigate the role of Lzts1 in paclitaxel-resistance in breast cancer cells. Downregulation of Lzts1 expression significantly decreases sensitivity to paclitaxel in vitro. We further analyzed Lzts1 expression by immunohistochemistry in 270 primary breast cancer samples and 16 normal breast specimens. Lzts1 was significantly downregulated in breast cancer samples and its deregulation was associated with a higher incidence of tumor recurrence, and to a worse overall survival. Moreover, Lzts1-negative tumors were associated with unfavorable outcome after taxanes-based therapy. Thus our data suggest that Lzts1 deregulation is involved in breast cancer and its immunohistochemical evaluation may serve as a prognostic factor for breast cancer therapy.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84897469173&origin=inward; http://dx.doi.org/10.18632/oncotarget.1630; http://www.ncbi.nlm.nih.gov/pubmed/24448468; https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.1630; https://dx.doi.org/10.18632/oncotarget.1630; https://www.oncotarget.com/article/1630/text/; http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=1630&path%5B%5D=1820; https://www.oncotarget.com/article/1630/; https://www.oncotarget.com/article/1630/pdf/; http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=1630; http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5b%5d=1630; http://www.oncotarget.com/fulltext/1630; http://oncotarget.com/abstract/1630
Impact Journals, LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know